14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
ACHC vs SGRY: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Acadia Healthcare Company, Inc. (ACHC) is the stronger overall head-to-head candidate over Surgery Partners, Inc. (SGRY) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). ACHC carries a Unified Composite Score of 33.1/100 (SELL) at $34.60 (17.0x Forward P/E, 9.8% operating margin), whereas SGRY carries 29.6/100 (SELL) at $26.78 (N/M Forward P/E, 13.2% operating margin).
Defensive Composite Rating Caution: Although ACHC compares more favorably head-to-head, both ACHC (33.1/100 SELL) and SGRY (29.6/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
Competes within the Medical Care Facilities value chain with $3.5B market capitalization and 13.2% operating margin.
OpEx & R&D Reinvestment9.0% of Rev ($302M)
90D Engineering Disclosures0 Published
Investor FAQ ACHC vs SGRY Key Questions & Quantitative Answers
As of Nov 20, 2026, Acadia Healthcare Company, Inc. (ACHC) is the stronger overall head-to-head candidate over Surgery Partners, Inc. (SGRY) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). ACHC carries a Unified Composite Score of 33.1/100 (SELL) at $34.60 (17.0x Forward P/E, 9.8% operating margin), whereas SGRY carries 29.6/100 (SELL) at $26.78 (N/M Forward P/E, 13.2% operating margin). Defensive Composite Rating Caution: Although ACHC compares more favorably head-to-head, both ACHC (33.1/100 SELL) and SGRY (29.6/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
ACHC leads the Growth & Scale pillar: ACHC posts +5.1% YoY revenue growth and -5.1% YoY earnings growth on $3.41B TTM revenue (41.0% gross margin, 9.8% operating margin), compared with SGRY at -0.8% YoY revenue growth and +0.0% YoY earnings growth on $3.36B TTM revenue (22.2% gross margin, 13.2% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), ACHC cumulative revenue shifted +74.2% while SGRY shifted +87.0%. In operating R&D and SG&A reinvestment, ACHC deploys 31.2% of Rev ($1.06B) (0 90-day corporate R&D disclosures) versus 9.0% of Rev ($302M) (0 disclosures) for SGRY.
ACHC screens cheaper on headline valuation multiples. ACHC trades at 17.0x Forward P/E, 16.9x Trailing P/E, 1.37x PEG, and 1.6x EV/Revenue (-0.7% FCF margin), whereas SGRY trades at N/M Forward P/E, N/M Trailing P/E, 1.66x PEG, and 1.9x EV/Revenue (6.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ACHC (-40.5% ROE) versus SGRY (2.1% ROE) capital efficiency.
In options market volatility and institutional positioning, ACHC carries 49.8% implied volatility (31st %ile, Balanced (25th–60th %ile)), a 0.39x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (0.68β · 61% Vol realized risk). By comparison, SGRY carries 62.1% implied volatility (34th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a SURGE options structure phase (0.87β · 166% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.